Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rich, S.
Right arrow Articles by Brundage, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rich, S.
Right arrow Articles by Brundage, B. H.

Chest, Vol 91, 356-360, Copyright © 1987 by American College of Chest Physicians

ARTICLES

Thromboxane synthetase inhibition in primary pulmonary hypertension

S Rich, K Hart, K Kieras and BH Brundage

Thromboxane synthetase inhibitors have been shown to reduce thromboxane, a potent vasoconstrictor, and increase prostacyclin, a potent vasodilator, in normal subjects. We evaluated the acute and chronic (three months) effects of the thromboxane synthetase inhibitor CGS13080 administered 200 mg every six hours on the resting hemodynamics in ten patients with primary pulmonary hypertension (PPH), and on their response to 20 mg of nifedipine given sublingually before and after the thromboxane synthetase inhibitor treatment. It was concluded that one can modulate the levels of endogenous thromboxane and prostacyclin in patients with primary pulmonary hypertension using a thromboxane synthetase inhibitor. Although the thromboxane synthetase inhibitor alone produced only modest hemodynamic changes over time, the addition of nifedipine was able to produce a further lowering of pulmonary artery pressure and pulmonary vascular resistance.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
I. M. Robbins, S. M. Kawut, D. Yung, M. P. Reilly, W. Lloyd, G. Cunningham, J. Loscalzo, S. E. Kimmel, B. W. Christman, and R. J. Barst
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension.
Eur. Respir. J., March 1, 2006; 27(3): 578 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Kataoka, N. Nagaya, T. Satoh, T. Itoh, S. Murakami, T. Iwase, Y. Miyahara, S. Kyotani, Y. Sakai, K. Kangawa, et al.
A Long-Acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1575 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Li and J. N. Stallone
Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1542 - H1550.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. D. Fike, Y. Zhang, and M. R. Kaplowitz
Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets
J Appl Physiol, August 1, 2005; 99(2): 670 - 676.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Budhiraja, R. M. Tuder, and P. M. Hassoun
Endothelial Dysfunction in Pulmonary Hypertension
Circulation, January 20, 2004; 109(2): 159 - 165.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. T. Fulton and J. N. Stallone
Sexual dimorphism in prostanoid-potentiated vascular contraction: roles of endothelium and ovarian steroids
Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H2062 - H2073.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A J Peacock
Rare diseases bullet 5: Primary pulmonary hypertension
Thorax, December 1, 1999; 54(12): 1107 - 1118.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
M. Parviz, M. Bousamra II, J. H. Chammas, E. K. Birks, K. W. Presberg, E. R. Jacobs, and L. D. Nelin
Effects of chronic pulmonary overcirculation on pulmonary vasomotor tone
Ann. Thorac. Surg., February 1, 1999; 67(2): 522 - 527.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American College of Chest Physicians.